World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
105
Citations
38794
World Ranking
6798
National Ranking
3590

Overview

Yu-Tzu Tai is affiliated with Harvard University in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with significant contributions in multiple specialized subfields including Molecular Biology, Hematology, Oncology, Immunology, and Cancer Research.

The focus of their research is centered on topics such as Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Peptidase Inhibition and Analysis, CAR-T cell therapy research, Ubiquitin and proteasome pathways, Monoclonal and Polyclonal Antibodies Research, and Immune Cell Function and Interaction.

Some of the frequent co-authors collaborating with Yu-Tzu Tai include Kenneth C. Anderson, Nikhil C. Munshi, Teru Hideshima, Mehmet Samur, and Kenneth Wen.

Common publication venues for their research work are journals like Blood, Clinical Lymphoma Myeloma & Leukemia, Leukemia, Cancer Research, and Blood Cancer Journal.

Recent papers authored or co-authored by Yu-Tzu Tai include:

  • Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma (2021, Nature Communications)
  • Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression (2020, Journal of Clinical Oncology)
  • Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation (2021, Blood Cancer Discovery)
  • Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells (2020, Frontiers in Immunology)
  • Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy (2021, Blood Advances)

Best Publications

  • Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

    Teru Hideshima;Dharminder Chauhan;Dharminder Chauhan;Yoshihito Shima;Yoshihito Shima;Noopur Raje;Noopur Raje

  • Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

    Faith E. Davies;Noopur Raje;Noopur Raje;Noopur Raje;Teru Hideshima;Teru Hideshima;Teru Hideshima;Suzanne Lentzsch;Suzanne Lentzsch;Suzanne Lentzsch

  • Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors

    Michel De Weers;Yu Tzu Tai;Michael S. Van Der Veer;Joost M. Bakker

  • Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

    Niccolo Bolli;Hervé Avet-Loiseau;David C. Wedge;Peter Van Loo

  • The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.

    Nicholas Mitsiades;Constantine S. Mitsiades;Paul G. Richardson;Vassiliki Poulaki

  • Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer

    Gijs Van Haaften;Gillian L Dalgliesh;Helen Davies;Lina Chen

  • Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.

    D Gupta;S P Treon;Y Shima;T Hideshima

  • BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression

    Aldo M. Roccaro;Antonio Sacco;Patricia Maiso;Abdel Kareem Azab

  • Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

    Triona Ni Chonghaile;Kristopher A. Sarosiek;Thanh Trang Vo;Jeremy A. Ryan

  • Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

    Klaus Podar;Yu-Tzu Tai;Faith E. Davies;Suzanne Lentzsch

  • Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

    Yu Tzu Tai;Myles Dillon;Weihua Song;Merav Leiba

  • Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

    Mariateresa Fulciniti;Pierfrancesco Tassone;Teru Hideshima;Sonia Vallet

  • Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

    Yu Tzu Tai;Patrick A. Mayes;Chirag Acharya;Mike Y. Zhong

  • Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

    Naoya Mimura;Mariateresa Fulciniti;Gullu Gorgun;Yu Tzu Tai

  • Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

    Laurence Catley;Ellen Weisberg;Ellen Weisberg;Tanyel Kiziltepe;Tanyel Kiziltepe;Yu-Tzu Tai;Yu-Tzu Tai

  • A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.

    Guang Yang;Yangsheng Zhou;Xia Liu;Lian Xu

  • Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma.

    Rao H. Prabhala;Dheeraj Pelluru;Mariateresa Fulciniti;Harsha K. Prabhala

  • MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.

    Lian Xu;Zachary R. Hunter;Guang Yang;Yangsheng Zhou

  • A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.

    Ze Tian;Padraig D’Arcy;Xin Wang;Arghya Ray

  • B563 Anti-DKK1 mAb (BHQ880) as a Potential Therapeutic Agent for Multiple Myeloma

    M Fulciniti;S Vallet;S Ettenberg;X Shen

Frequent Co-Authors

Nikhil C. Munshi
Nikhil C. Munshi Harvard University
Kenneth C. Anderson
Kenneth C. Anderson Harvard University
Teru Hideshima
Teru Hideshima Harvard University
Paul G. Richardson
Paul G. Richardson Harvard University
Dharminder Chauhan
Dharminder Chauhan Harvard University
Klaus Podar
Klaus Podar Karl Landsteiner University of Health Sciences
Noopur Raje
Noopur Raje Harvard University
Steven P. Treon
Steven P. Treon Harvard University
Constantine S. Mitsiades
Constantine S. Mitsiades Harvard University
Robert L. Schlossman
Robert L. Schlossman Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in a career in Medicine and healthcare, there are several flexible online degree options to consider. For those seeking a quicker route into the workforce, lpn program options provide a fast-track path to becoming a Licensed Practical Nurse, which can be a valuable start in patient care.

Nursing professionals advancing their education can explore bsn to np programs online, opening doors to specialized nurse practitioner roles, such as psychiatric mental health. These programs offer flexibility for working nurses to deepen their expertise and climb the career ladder.

For those interested in leadership and management roles, pursuing an online master of health administration is an excellent way to transition into healthcare administration or management. Additionally, if affordability is a key concern, there are cheapest online mha programs available, allowing you to gain a quality education without financial strain.

Exploring these related online degrees and career pathways can help you build a rewarding future in medicine and healthcare, whether your interests lie in direct patient care or healthcare leadership.

Best Scientists Citing Yu-Tzu Tai

Trending Scientists

Recently Published Articles